Adial Pharmaceuticals Inc/$ADIL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
Ticker
$ADIL
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
5
ISIN
US00688A2050
Website
ADIL Metrics
BasicAdvanced
$4.8M
-
-$1.56
1.19
-
Price and volume
Market cap
$4.8M
Beta
1.19
52-week high
$1.21
52-week low
$0.22
Average daily volume
15M
Financial strength
Current ratio
1.985
Quick ratio
1.786
Profitability
EBITDA (TTM)
-8.706
Management effectiveness
Return on assets (TTM)
-107.38%
Return on equity (TTM)
-217.01%
Valuation
Price to book
0.94
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
-0.252
Free cash flow yield (TTM)
-396.17%
Free cash flow per share (TTM)
-119.72%
Growth
Earnings per share change (TTM)
-66.00%
3-year earnings per share growth (CAGR)
-58.28%
ADIL News
AllArticlesVideos
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
GlobeNewsWire·6 days ago
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adial Pharmaceuticals Inc stock?
Adial Pharmaceuticals Inc (ADIL) has a market cap of $4.8M as of July 01, 2025.
What is the P/E ratio for Adial Pharmaceuticals Inc stock?
The price to earnings (P/E) ratio for Adial Pharmaceuticals Inc (ADIL) stock is 0 as of July 01, 2025.
Does Adial Pharmaceuticals Inc stock pay dividends?
No, Adial Pharmaceuticals Inc (ADIL) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Adial Pharmaceuticals Inc dividend payment date?
Adial Pharmaceuticals Inc (ADIL) stock does not pay dividends to its shareholders.
What is the beta indicator for Adial Pharmaceuticals Inc?
Adial Pharmaceuticals Inc (ADIL) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.